TITAN Group’s Credit Rating Improved to “BB+ with Positive Outlook” by S&P Global Ratings November 7, 2025 S&P Global Ratings has revised TITAN SA’s (Brussels:TITC) outlook to ‘Positive’ while affirming its ‘BB+’ long-term credit rating. This decision reflects TITAN Group’s continued robust financial performance and the effectiveness of its supportive financial policies. S&P’s report highlights the Group’s resilient results driven by its strong operations. The positive outlook demonstrates S&P views that they [...]
Soho House & Co Inc. Announces Third Quarter 2025 Results November 7, 2025 Soho House & Co Inc. (NYSE: SHCO) (“SHCO,” “Company,” “we” or “our”), a global membership platform that connects a vibrant, diverse, and global group of members, today announced results for the third quarter ended September 28, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107045088/en/ Third Quarter 2025 Highlights Total revenues of [...]
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights November 6, 2025 Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million Roche to initiate the Phase 3 PARAISO clinical trial evaluating prasinezumab, a potential first-in-class anti-alpha-synuclein antibody, for early-stage Parkinson's disease by end of 2025 Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial evaluating coramitug, a potential first-in-class amyloid depleter, for ATTR amyloidosis with cardiomyopathy Novo Nordisk to present Phase 2 results for coramitug during a late-breaking session at the American Heart Association Scientific Sessions on November 10, 2025 Bristol Myers Squibb obtained Fast Track designation from the U.S. FDA for BMS-986446 (PRX005), an anti-MTBR-tau-targeting antibody, for the treatment of Alzheimer’s disease Prothena will convene an Extraordinary General Meeting on November 19, 2025 to obtain shareholder approval on a proposal reducing share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
TITAN Group Enters Into Exclusive Negotiations to Acquire Vracs de L’Estuaire Cementitious Business in France Strengthening its Presence in Western Europe November 6, 2025 TITAN Group has entered into exclusive negotiations to acquire Vracs de L’Estuaire, a Company with state-of-the-art facilities, including a grinding plant located at the port of Le Havre in Northern France. The facility is ideally positioned to serve one of the largest and fastest-growing markets in Europe. This strategic investment strengthens TITAN’s presence in France, [...]
Game Developers Can Now Strengthen Player Loyalty and Security With Xsolla’s Expanded Fintech Ecosystem This Holiday Season November 6, 2025 Xsolla Gold Expansion, Xsolla Pay Loyalty Program, and Network Tokens Create a Unified Framework for Secure, Rewarding Transactions
FIM Partners and Loomis Sayles Announce Transition of Global Emerging Market Equities Team November 6, 2025 FIM Partners today announced it has entered into an agreement with Loomis, Sayles & Company, to acquire the Global Emerging Market Equities (GEM) investment team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106799715/en/ Overview of the GEM Team and FIM Led by Ashish Chugh, Portfolio Manager and Head of Global Emerging Market [...]
From insights to impact, Leinster Rugby leverages data strategy to level up fan experience November 6, 2025 BearingPoint supports the club in creating a roadmap for personalized experiences and future-ready innovation.
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights November 6, 2025 SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028
Wireless Mobility Automotive becomes a 100% German-owned company strengthening its role as a trusted Western supplier November 6, 2025 Wireless Mobility, a leading provider of advanced cellular, automotive, smart and short-range modules, today announces that Wireless Mobility Automotive has become a wholly owned subsidiary of Wireless Mobility Holding GmbH, making the company a 100% German-owned enterprise. This milestone reinforces the company’s position as a transparent and independent Western supplier, fully aligned with the US [...]
Vena Solves FP&A Data Fragmentation With Six New Microsoft Fabric Data Integrations November 6, 2025 Launch includes first Microsoft Dynamics 365 F&O connector for FP&A, simplifying data integration and enabling AI-powered finance